Biogen (BIIB) Total Non-Current Liabilities (2009 - 2026)

Biogen has reported Total Non-Current Liabilities for 18 years, with the latest figure at $12.4 billion in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 25.47% year-over-year to $12.4 billion in Q2 2026; TTM through Jun 2026 was $12.4 billion, a 25.47% increase from a year earlier, with the FY2025 full-year figure at $10.4 billion, down 1.57% from the prior year.
• Total Non-Current Liabilities was $12.4 billion for Q2 2026 at Biogen, up from $10.0 billion in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $13.0 billion in Q3 2023, with the low at $9.9 billion in Q1 2023.
• Average Total Non-Current Liabilities over 5 years is $10.8 billion, with a median of $10.5 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities slipped 17.68% in 2023, then grew 25.47% in 2026.
• Over 5 years, Total Non-Current Liabilities stood at $10.2 billion in 2022, then climbed by 10.2% to $11.3 billion in 2023, then retreated by 5.89% to $10.6 billion in 2024, then fell by 1.57% to $10.4 billion in 2025, then advanced by 19.01% to $12.4 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $12.4 billion (Q2 2026), $10.0 billion (Q1 2026), and $10.4 billion (Q4 2025), per Business Quant data.